Monday, January 13, 2014
An increase in regulatory
approvals and new breakthrough therapies has money managers buying into the
concept that biotech has entered a new product cycle that provides a strong
fundamental basis for growth. They are looking for a slew of clinical,
regulatory and commercial milestones to continue to drive the industry in 2014.
Investors who participated in
BioCentury's 22nd annual Buyside View survey broadly agree the biotech bull run
of 2013 - unlike that of 2000 - wasn't driven by hype, but by fundamentals.